万珂在特殊人群的应用及安全性管理-培训课件.pptVIP

* /cgi/content/abstract/24/18_suppl/2032 A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function D. Mulkerin, S. Remick, R. Ramanathan, A. Hamilton, C. Takimoto, A. Davies, P. Ivy, M. Karol, J. Kolesar, J. Wright NCI Organ Dysfunction Working Group 2006ASCO 2032 Background: Bortezomib is a highly selective and reversible inhibitor of the proteasome with activity in multiple myeloma and other malignancies. Patients (pts) with renal impairment have been treated in previous trials, but there has not been a systematic investigation into the